
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx Inc has demonstrated strong financial fundamentals, with a 21% top-line growth in Q3, supported by a 13% increase in volume and a 5% rise in average selling prices, alongside achieving its highest cash collections in history in October. The company has notably expanded its sales force by approximately 50%, which is expected to enhance volume growth further, following a solid 19% year-over-year increase in kidney surveillance volumes reported in Q2'25. Additionally, CareDx achieved GAAP net income positivity and raised its revenue guidance, reflecting positive momentum that helped boost its stock by 10%.
Bears say
CareDx Inc. has reported Q3'25 testing volumes of 50,000, which, while representing a 13% year-over-year increase, fell short of expectations and experienced seasonal slowdowns. The company's shares have faced downward pressure, trading at a low multiple of 1.4 times projected revenues for 2026, significantly below historical averages and peers within the diagnostics sector. Additionally, ongoing management turnover and uncertainties surrounding the commercialization of new diagnostic solutions raise significant concerns over the company’s growth trajectory and competitive positioning in the market.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares